Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology

Sector: Healthcare

Phone: 605 679 6980

Website: www.sabbiotherapeutics.com

Address:

777 W 41st St., Miami Beach, United States

b3akohe Aug. 5 at 1:56 PM

$SABS finally starting to show some strength. Very beaten up stock . Lots of real potential here . We can double from here in a minute. Expect a big move up any time

0 · Reply

JTebow_CWS Aug. 3 at 7:30 PM

$SABS Andrew Moin M&A Attorney Form 4 Why is his Warrant exercise price so high? @RRGM @IcahnSoCanU

1 · Reply

JTebow_CWS Aug. 2 at 9:13 PM

$SABS The stock is not the company and the company is not the stock. SABS doesn’t need to come back to the capital markets. They don’t need us. They are fully funded. Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, (former JDRF) and ATW. PartnersProceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3)Company expects proceeds to extend cash runway into the middle of 2028 Potential for up to an additional $284 million of gross proceeds if milestone-based warrants exercised in full. https://youtu.be/msFwJ5xpg_g?si=5NhtGGk8PFdajk2Y

1 · Reply

JTebow_CWS Aug. 2 at 7:48 PM

$SABS Understanding serum sickness. What most would call an allergic reaction to medications. Polyclonal antibodies found in colostrum have been a natural source of immunity or an assistance to our natural immunity for thousands of year. SAB BIO’s proprietary platform offers assistance to our natural immune system without any side effects. Zero side effects. The public is tired of accepting risk and signing away their life on a consent form. It’s time that we in medicine perfect our treatments medications to low or no side effects. https://youtube.com/shorts/E7DLZ0WRi44?si=kVIdG2wJ_XBPZhng

0 · Reply

JTebow_CWS Aug. 2 at 2:54 AM

$SABS Instagram post by Ginger Vieira T1D.

0 · Reply

S2K_TradeZ Aug. 1 at 5:36 PM

$SABS swing idea 🚨🎢

0 · Reply

JTebow_CWS Aug. 1 at 1:56 AM

$SABS $SNY $REGN Accumulation with lunch money daily.

0 · Reply

DDiamond_Handz Jul. 31 at 10:03 PM

$SABS

0 · Reply

smolcapcat Jul. 31 at 7:36 PM

$SABS total collapse ahhhhh

0 · Reply

Quid_Pro_Quo Jul. 31 at 2:53 PM

$SABS First down to 1.75 and from there up?

1 · Reply

SAB BIO Announces Oversubscribed $175 Million Private Placement

May 9, 2025, 9:00 AM EDT - 3 months ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

Mar 31, 2025, 7:32 AM EDT - 4 months ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Jan 31, 2025, 7:00 AM EST - 6 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Jan 28, 2025, 3:40 PM EST - 6 months ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 7:00 AM EST - 6 months ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 6 months ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 6, 2024, 5:05 PM EST - 9 months ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Sep 13, 2024, 7:00 AM EDT - 11 months ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 1 year ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 1 year ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 21, 2024, 7:15 AM EDT - 1 year ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 6, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Mar 29, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 25, 2024, 10:15 AM EDT - 1 year ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Feb 23, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Executive Leadership Change

Jan 23, 2024, 5:58 PM EST - 1 year ago

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 4:30 PM EST - 1 year ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Nov 29, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 20, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Nov 14, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 14, 2023, 7:15 AM EST - 1 year ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Nov 9, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

Oct 24, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Oct 19, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Oct 5, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

Oct 2, 2023, 7:30 AM EDT - 2 years ago

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Aug 21, 2023, 8:30 AM EDT - 2 years ago

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

Jun 21, 2023, 8:30 AM EDT - 2 years ago

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

b3akohe Aug. 5 at 1:56 PM

$SABS finally starting to show some strength. Very beaten up stock . Lots of real potential here . We can double from here in a minute. Expect a big move up any time

0 · Reply

JTebow_CWS Aug. 3 at 7:30 PM

$SABS Andrew Moin M&A Attorney Form 4 Why is his Warrant exercise price so high? @RRGM @IcahnSoCanU

1 · Reply

JTebow_CWS Aug. 2 at 9:13 PM

1 · Reply

JTebow_CWS Aug. 2 at 7:48 PM

0 · Reply

JTebow_CWS Aug. 2 at 2:54 AM

$SABS Instagram post by Ginger Vieira T1D.

0 · Reply

S2K_TradeZ Aug. 1 at 5:36 PM

$SABS swing idea 🚨🎢

0 · Reply

JTebow_CWS Aug. 1 at 1:56 AM

$SABS $SNY $REGN Accumulation with lunch money daily.

0 · Reply

DDiamond_Handz Jul. 31 at 10:03 PM

$SABS

0 · Reply

smolcapcat Jul. 31 at 7:36 PM

$SABS total collapse ahhhhh

0 · Reply

Quid_Pro_Quo Jul. 31 at 2:53 PM

$SABS First down to 1.75 and from there up?

1 · Reply

JTebow_CWS Jul. 31 at 3:18 AM

$SABS $SNY $REGN Super bullish with polyclonal antibodies. Thankful to be holding shares in a revolutionary Type 1 DM prevention treatment.

1 · Reply

JTebow_CWS Jul. 31 at 12:18 AM

$SABS Interview starts at 18:00. Ends at 34:25 Plausible mechanism pathway. This is a new policy that allows for regulatory, flexibility, and leeway. Some drugs won’t even require full phase 1,2, or 3 trials. https://podcasts.apple.com/us/podcast/squawk-pod/id1480890290?i=1000719814078

0 · Reply

AlphaJungle Jul. 30 at 6:52 PM

$SABS So 100m shares at $1.75? This is gonna get diluted 1ox from current 10m o/s share count

0 · Reply

DDiamond_Handz Jul. 28 at 4:37 PM

$SABS

0 · Reply

JTebow_CWS Jul. 28 at 2:41 PM

$SABS If Sanofi pays the same amount for SAB BIO for SAB-142 as they paid for TZIELD. Considering there is Less than 10 million outstanding share count. Look at the stock price.

4 · Reply

JTebow_CWS Jul. 28 at 2:38 PM

$SABS Provention Bio maker of TZIELD was bought by Sanofi for 2.9 billion. Or $25 a share. https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367

1 · Reply

JTebow_CWS Jul. 27 at 2:58 AM

$SABS The opportunity before us is incredible. I don’t think there is a better opportunity on the NYSE/NASDAQ than SABS. Considering, I’m a large share holder of ASTS. I love my SpaceMob crew as if I was in the military. I won’t sell my blood shares below $3. On the other hand. Why do I find opportunities like SABS? Hope yall can see what I see. God bless jt Don’t ever listen me. I’m always wrong.

1 · Reply

StockSenseiTrendTraders Jul. 25 at 5:09 PM

🚨Weekly Recap (7/21–7/25)🚨 Top 5 Alerts from the week 34W/4L: 1️⃣ $SABS +65.00% 2️⃣ $HTOO +44.95% 3️⃣ $HSDT +37.21% 4️⃣ $PAPL +33.57% 5️⃣ $AMOD +32.65% 📈 2025 Performance Highlights ✅ Wins: 775 ❌ Losses: 57 💥 Gain Potential: +35,219% 📊 Avg Gain/Winning Alert: 45.44% Even in slower weeks, we still find winners. Join our Zooms and let’s keep stacking!

0 · Reply

JTebow_CWS Jul. 25 at 2:54 AM

$SABS Andrew Moin introduction. Acquired both shares and warrants. Buyout

1 · Reply

JTebow_CWS Jul. 24 at 9:30 PM

$SABS https://youtube.com/shorts/YLpRdNfufeQ?si=lKj1x_OS0BLJYL0z

1 · Reply

JTebow_CWS Jul. 24 at 9:29 PM

$SABS Tzield (teplizumab-mzwv) and its Mechanism of action is already well understood by the FDA. Any serum sickness observed prevents a possible re-dosing. SAB-142 will get approved as a superior treatment for C-peptide preservation. And delay the onset of T1D. Excited. https://youtu.be/d_yCEvKD10Y?si=Z-YBAsQ8ZE8hN3ZQ

1 · Reply

_www_larval_com_ Jul. 24 at 7:57 PM

$MFH -3%[53%] $SABS -3%[3%] $GALT -3%[5%] $BZAI 3%[-16%] most notable movement into the final minutes of trading.

0 · Reply

Market Cap	21.18M
Revenue (ttm)	1.32M
Net Income (ttm)	-34.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,584.09%
Debt to Equity Ratio	0.00

Volume	116,700
Avg Vol	1,748,642
Day's Range	N/A - N/A
Shares Out	9.29M
Stochastic %K	45%
Beta	0.53
Analysts	Strong Sell
Price Target	$11.60